Abstracts tagged "administrative databases"

Abstract Number: 1525 • 2017 ACR/ARHP Annual Meeting
Characteristics and Treatment Patterns Among Patients with Psoriatic Arthritis Initiating Subcutaneously Administered Biologics: Descriptive Analyses from a US Claims Database
Kurt R. Oelke¹, Rahul Garg², Peter Hur³, Olivier Chambenoit³, Amar Q. Majjhoo⁴, Stephani Gray⁵, Kate Higgins⁵ and Jacqueline B. Palmer³, ¹Rheumatic Disease Center, Glendale, WI, ²PRO Unlimited, Inc, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Shores Rheumatology, St. Clair Shores, MI, ⁵Truven Health Analytics, Cambridge, MA
Background/Purpose: To better understand the real-world efficacy of biologics for the treatment of psoriatic arthritis (PsA), there is a need to evaluate the persistence and…
Abstract Number: 1963 • 2017 ACR/ARHP Annual Meeting
Association of Corticosteroid Exposure with Ophthalmologic Complications and Systemic Adverse Events in Non-Infectious Uveitis Patients Using Administrative Claims in the United States
Nisha Acharya¹, Keith A. Betts², Oscar Patterson-Lomba², Arijit Ganguli³, Sophie Schonfeld² and Jenny Griffith³, ¹University of California San Francisco, San Francisco, CA, ²Analysis Group, Inc., Boston, MA, ³AbbVie Inc., North Chicago, IL
Background/Purpose: Noninfectious uveitis (NIU) is a collection of intraocular inflammatory disorders associated with significant visual impairment. Corticosteroids (CS) are typically the first-line drug therapy for…
Abstract Number: 2593 • 2017 ACR/ARHP Annual Meeting
Baseline Characteristics of Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab
Christopher F Bell¹, Julie Priest^2,3, Justyna Amelio⁴, Xue Song⁵, Hong Kan⁶, Marni Stott-Miller⁷, Brendan Limone⁵, Virginia Noxon⁵ and Karen H. Costenbader⁸, ¹GSK US Value, Evidence and Outcomes, Research Triangle Park, NC, ²GSK US Value, Evidence and Outcomes (at the time of Study)*, Research Triangle Park, NC, ³US Health Outcomes Durham, *ViiV Healthcare (Present), Durham, NC, ⁴GSK Real World Evidence & Epidemiology, Stevenage, United Kingdom, ⁵Truven Health Analytics, an IBM company, Ann Arbor, MI, ⁶Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁷GSK Real World Evidence & Epidemiology, Uxbridge, United Kingdom, ⁸Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Belimumab, an inhibitor of B lymphocyte stimulator, is approved in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard of care. Methods: Retrospective…
Abstract Number: 2594 • 2017 ACR/ARHP Annual Meeting
Frequency of Infusions Among Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab
Christopher F Bell¹, Julie Priest^2,3, Marni Stott-Miller⁴, Hong Kan⁵, Justyna Amelio⁶, Xue Song⁷, Brendan Limone⁷, Virginia Noxon⁷ and Karen H. Costenbader⁸, ¹GSK US Value, Evidence and Outcomes, Research Triangle Park, NC, ²GSK US Value, Evidence and Outcomes (at the time of Study)*, Research Triangle Park, NC, ³US Health Outcomes Durham, *ViiV Healthcare (Present), Durham, NC, ⁴GSK Real World Evidence & Epidemiology, Uxbridge, United Kingdom, ⁵Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁶GSK Real World Evidence & Epidemiology, Stevenage, United Kingdom, ⁷Truven Health Analytics, an IBM company, Ann Arbor, MI, ⁸Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Belimumab, an inhibitor of B lymphocyte stimulator, is approved for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard…
Abstract Number: 2812 • 2017 ACR/ARHP Annual Meeting
Healthcare Resource Utilization and Costs in Patients with Systemic Lupus Erythematosus before and after Initiating Treatment with Intravenous Belimumab: A US Claims Database Analysis
Christopher F Bell¹, Julie Priest^2,3, Marni Stott-Miller⁴, Hong Kan⁵, Justyna Amelio⁶, Xue Song⁷, Brendan Limone⁷, Virginia Noxon⁷ and Karen H. Costenbader⁸, ¹GSK US Value, Evidence and Outcomes, Research Triangle Park, NC, ²GSK US Value, Evidence and Outcomes (at the time of Study)*, Research Triangle Park, NC, ³US Health Outcomes Durham, *ViiV Healthcare (Present), Durham, NC, ⁴GSK Real World Evidence & Epidemiology, Uxbridge, United Kingdom, ⁵Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁶GSK Real World Evidence & Epidemiology, Stevenage, United Kingdom, ⁷Truven Health Analytics, an IBM company, Ann Arbor, MI, ⁸Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Belimumab, an inhibitor of B lymphocyte stimulator, is approved in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard of care. There is…
Abstract Number: 96 • 2016 ACR/ARHP Annual Meeting
Transforming Healthcare in Rheumatology: From Inpatient to Outpatient Care without Reductions in Healthcare Quality
Andreas P Diamantopoulos^1,2 and Timothy T Brown¹, ¹Public Health, University of California, Berkeley, Berkeley, CA, ²Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway
Background/Purpose: The implementation of a major program to improve the quality of care in inflammatory arthritides (rheumatoid arthritis-RA, spondyloarthritis- SpA and psoriatic arthritis- PsA) included…
Abstract Number: 1810 • 2016 ACR/ARHP Annual Meeting
Health Care Utilization Preceding Diagnosis of Systemic Lupus Erythematosus in Youth
Joyce Chang¹, Colleen Brensinger², Liu Qing² and Andrea Knight^1,3,4, ¹Division of Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Early diagnosis and treatment of youth with SLE are crucial to prevent organ damage and reduce mortality. Understanding health care utilization prior to diagnosis…
Abstract Number: 2079 • 2016 ACR/ARHP Annual Meeting
Incidence and Risk of Pneumocystis Jirovecii Pneumonia Following Rituximab Treatment in Granulomatosis with Polyangiitis in the United States: An Analysis from a National Database
Sirada Panupattanapong¹, Anthony R. French², Andrew J. White², Margaret A. Olsen³, Maya Rendulic⁴ and Mary E. Hartman⁵, ¹Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ²Division of Pediatric Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ³Division of Infectious Disease, Washington University School of Medicine, St. Louis, MO, ⁴Center for Administrative Data Research, Washington University School of Medicine, St. Louis, MO, ⁵Division of Pediatric Critical Care Medicine, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO
Background/Purpose: Pneumocystis Jirovecii pneumonia (PJP) is a life-threatening complication in granulomatosis with polyangiitis (GPA). Guidelines from EULAR for ANCA-associated vasculitis (AAV) recommend institution of PJP…
Abstract Number: 2230 • 2016 ACR/ARHP Annual Meeting
Models Using Claims-Based Administrative Data Are Poor Predictors of Rheumatoid Arthritis Disease Activity in VA Rheumatoid Arthritis (VARA) Patients
Brian Sauer¹, Chia-Chen Teng², Neil Accortt³, Zachary Burningham⁴, David Collier⁵, Mona Trivedi⁶ and Grant W. Cannon⁷, ¹IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Center for Observational Research, Amgen, Inc., C, CA, ⁴SLC Veterans Affairs Medical Center, SLC IDEAS Center, Salt Lake City, UT, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Amgen, Thousand Oaks, CA, ⁷Internal Medicine, Veterans Affairs Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT
Background/Purpose: The goal of this study was to validate a claims-based statistical model to predict disease activity measured by the 28-joint count Disease Activity Score…
Abstract Number: 2323 • 2016 ACR/ARHP Annual Meeting
Evaluation of Case-Finding Algorithms for Identification of Patients with Dermatomyositis
Kevin Byram¹ and Narender Annapureddy², ¹Internal Medicine, Vanderbilt University, Nashville, TN, ²Rheumatology and Immunology, Vanderbilt University, Nashville, TN
Background/Purpose: In order to enable meaningful clinical care and research, accurate algorithms are needed to identify patients with dermatomyositis (DM). In this study, we aimed…
Abstract Number: 1534 • 2015 ACR/ARHP Annual Meeting
Temporal Trends and Outcomes of Acute Myocardial Infarction in Rheumatoid Arthritis Hospitalizations
Narender Annapureddy¹, Achint Patel², Rabi Yacoub³, Krishna Pakanati⁴, Shiv Agarwal⁵, Priya Simoes⁶, Shaan Patel³, Sunil Kamat⁷, Alexandre Benjo⁸ and Girish Nadkarni⁹, ¹Rheumatology and Immunology, Vanderbilt University, Nashville, TN, ²Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Gateway Medical Center, Clarksville, TN, ⁵Cardiology, University of Arkansas Medical Sciences, Little Rock, AR, ⁶Internal Medicine, St.Lukes Roosevelt Hospital Center at Mount Sinai, New York, NY, ⁷Critical Care, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India, ⁸Ochsner Clinic Foundation, New Orleans, NY, ⁹Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of cardiac mortality. With better treatment modalities, some studies suggest that infarction (AMI) mortality in RA…
Abstract Number: 2048 • 2015 ACR/ARHP Annual Meeting
Hospitalization Trends of Rheumatoid Arthritis and Gout in the United States: A Crossroad
Sian Yik Lim¹, Na Lu¹, Mark Fisher¹, Amar Oza¹, Sharan K. Rai², Mariano E Menendez¹ and Hyon Choi¹, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Experimental Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Rheumatoid arthritis (RA) and gout are the two most common inflammatory arthritides in the US and beyond. As hospitalization for these conditions are known…
Abstract Number: 40 • 2015 ACR/ARHP Annual Meeting
Increased Mortality in Indigenous North Americans Persons with Rheumatoid Arthritis Is Partially Explained By Psychiatric and Physical Comorbidity: a Population Based Study
Carol Hitchon¹, Sazzadul Khan², Brenda Elias³, Alan Katz⁴ and Christine A. Peschken⁵, ¹Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Manitoba Centre for Health Policy and Research, University of Manitoba, Winnipeg, MB, Canada, ³Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁴Manitoba Centre for Health Policy, University of Manitoba, Winnipeg, MB, Canada, ⁵Arthritis Center, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Rheumatoid Arthritis (RA) is associated with excess mortality. Indigenous North Americans (INA) in our region have high RA prevalence rates and young age at onset yet experience…
Abstract Number: 121 • 2015 ACR/ARHP Annual Meeting
Serum Uric Acid Levels and Gout Flares in a US Managed Care Setting
Aki Shiozawa¹, Erin Buysman², Stephanie Korrer² and Hyon Choi³, ¹Global Outcomes and Epidemiology Research, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ²Health Economics and Outcomes Research, Optum, Eden Prairie, MN, ³Massachussetts General Hospital/Harvard Medical School, Boston, MA
Background/Purpose: Gout is a common chronic inflammatory condition due to hyperuricemia. Gout patients typically have the clinical manifestation of acute painful flare attacks. While the…
Abstract Number: 149 • 2015 ACR/ARHP Annual Meeting
Characteristics of Patients Diagnosed with Systemic Lupus Erythematosus (SLE) Initiating Treatment with Belimumab in a US Commercially Insured Database: 2010-2014
Deanna Hill¹, Hong Kan², Peter Egger³, David J. Chang⁴, Amanda Eudy^1,5, Joe Maskell³ and Karen H. Costenbader⁶, ¹Worldwide Epidemiology, GlaxoSmithKline, Collegeville, PA, ²Value Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC, ³Worldwide Epidemiology, GlaxoSmithKline, Stockley Park, United Kingdom, ⁴US Medical Affairs, GlaxoSmithKline, Philadelphia, PA, ⁵Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, ⁶Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Belimumab, a B-lymphocyte stimulator, was FDA-approved March 2011 for the treatment of adult patients with active, autoantibody-positive SLE receiving standard of care (SOC) medications.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].